News Image

Evaluating NASDAQ:ETON for Growth Investment Opportunities.

By Mill Chart

Last update: Jan 22, 2024

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if ETON PHARMACEUTICALS INC (NASDAQ:ETON) is suited for growth investing. Investors should of course do their own research, but we spotted ETON PHARMACEUTICALS INC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

Looking into the growth metrics of ETON PHARMACEUTICALS INC

  • ETON PHARMACEUTICALS INC has a healthy Return on Equity(ROE) of 13.2%. This demonstrates the company's efficient utilization of capital and indicates its commitment to driving profitability.
  • ETON PHARMACEUTICALS INC has a strong history of beating EPS estimates in the last 4 quarters, signaling its ability to consistently exceed market expectations. This indicates the company's strong financial performance and its potential for creating shareholder value.
  • With impressive 1-year revenue growth of 74.16%, ETON PHARMACEUTICALS INC showcases its ability to generate increased sales and revenue. This growth highlights the company's strong customer demand and its effective business strategies.
  • The q2q revenue growth of 118.0% of ETON PHARMACEUTICALS INC highlights the company's ability to generate incremental revenue and suggests positive market demand for its products or services.
  • With positive growth in its operating margin over the past year, ETON PHARMACEUTICALS INC showcases its ability to improve profitability through effective cost control and operational efficiency. This growth underscores the company's commitment to enhancing its financial performance.
  • With positive growth in its free cash flow (FCF) over the past year, ETON PHARMACEUTICALS INC showcases its ability to generate strong cash flows and maintain a solid financial position. This growth reflects the company's efficient utilization of capital and its commitment to long-term value creation.
  • The quarterly earnings of ETON PHARMACEUTICALS INC have shown a 83.33% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
  • Over the past 3 months, analysts have adjusted their EPS Estimate for ETON PHARMACEUTICALS INC with a 42.86% change. This highlights the evolving outlook on the company's EPS potential.
  • The recent financial report of ETON PHARMACEUTICALS INC demonstrates a 83.33% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
  • The earnings per share (EPS) growth of ETON PHARMACEUTICALS INC are accelerating: the current Q2Q growth of 83.33% is above the previous year Q2Q growth of 50.0%. Earnings momentum and acceleration are key for high growth systems.

How does the complete fundamental picture look for NASDAQ:ETON?

Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.

ETON gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 205 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ETON get a neutral evaluation. Nothing too spectacular is happening here. ETON is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!

Check the latest full fundamental report of ETON for a complete fundamental analysis.

More growth stocks can be found in our Lois Navellier screen.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

ETON PHARMACEUTICALS INC

NASDAQ:ETON (5/24/2024, 7:25:10 PM)

3.58

-0.02 (-0.56%)

ETON News

News Image18 days ago - InvestorPlaceETON Stock Earnings: Eton Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024

ETON stock results show that Eton Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image18 days ago - BusinessInsiderETON Stock Earnings: Eton Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eton Pharmaceuticals (NASDAQ:ETON) just reported results for the first quarter ...

News Image18 days ago - Eton PharmaceuticalsEton Pharmaceuticals Reports First Quarter 2024 Financial Results
News Image18 days ago - Eton PharmaceuticalsEton Pharmaceuticals Reports First Quarter 2024 Financial Results

•  Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth•  Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400•  Management to hold conference call today at 4:30pm ET

News Imagea month ago - Eton PharmaceuticalsEton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
News Imagea month ago - Eton PharmaceuticalsEton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing...

News Imagea month ago - Eton PharmaceuticalsEton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
News Imagea month ago - Eton PharmaceuticalsEton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak...

News Imagea month ago - Eton PharmaceuticalsEton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
News Imagea month ago - Eton PharmaceuticalsEton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the

News Image2 months ago - Eton PharmaceuticalsEton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
News Image2 months ago - Eton PharmaceuticalsEton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is...

ETON Links
Follow us for more